>
Etropal AD logo

ETR - Etropal AD Share Price

BGN5.7 0.0  0.0%

Last Trade - 14/05/21

Sector
Healthcare
Size
Micro Cap
Market Cap £12.6m
Enterprise Value £13.8m
Revenue £3.29m
Position in Universe 479th / 649
Bullish
Bearish
Unlock ETR Revenue
Momentum
Relative Strength (%)
1m +0.26%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -1.72%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
7.91 6.70 7.40 8.30 6.73 7.46 -1.2%
-63.9 -40.6 -41.3 +117.7 -87.7 +8.5
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, EtropalAD revenues increased 11% to BGN7.5M. Net income increasedfrom BGN9K to BGN19K. Revenues reflect Sales of Servicesincrease of 63% to BGN1.1M, Sales of Products increase of6% to BGN6.2M. Net income benefited from Interest Expensesdecrease of 11% to BGN229K (expense), Depreciation Expense,Supplemental decrease of 3% to BGN524K (expense), OtherFinancial Income increase of 81% to BGN29K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ETR
Graphical History

Revenue

ETR Revenue Unlock ETR Revenue

Net Income

ETR Net Income Unlock ETR Revenue

Normalised EPS

ETR Normalised EPS Unlock ETR Revenue

PE Ratio Range

ETR PE Ratio Range Unlock ETR Revenue

Dividend Yield Range

ETR Dividend Yield Range Unlock ETR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ETR EPS Forecasts Unlock ETR Revenue
Profile Summary

Etropal AD is a Bulgaria-based company, which specializes in the scientific research, experimental and development activities in the field of orthopedics and traumatology. The Company manufactures and offers endoprothesys and implants, special bioceramic materials and alloys for the medicine, special surgical instruments, osteosynthesys means, single use syringes, haemodialysis apparatuses and lines and single use medical materials. The Company’s product portfolio includes fiber dialyzers, arterial and venous lines for haemodialysis, transfusion and infusion sets, fistula and injection needles, catheters, tubes, and femoral implants, among others. The Company operates through one subsidiary, Etropal Trade OOD. As of December 31, 2011, the Company’s major shareholder was Sintetika AD with a stake of 66.53%.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated April 2, 1990
Public Since November 7, 2007
No. of Shareholders: n/a
No. of Employees: 244
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange Bulgarian Stock Exchange
Shares in Issue 5,000,000
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ETR Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ETR
Upcoming Events for ETR
Thursday 30th September, 2021 Estimate
Etropal AD Annual Shareholders Meeting
Frequently Asked Questions for Etropal AD
What is the Etropal AD share price?

As of 14/05/21, shares in Etropal AD are trading at BGN5.7, giving the company a market capitalisation of £12.6m. This share price information is delayed by 15 minutes.

How has the Etropal AD share price performed this year?

Shares in Etropal AD are currently trading at BGN5.7 and the price has moved by -0.87% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Etropal AD price has moved by -24.45% over the past year.

What are the analyst and broker recommendations for Etropal AD?

There are no analysts currently covering Etropal AD.

When will Etropal AD next release its financial results?

Etropal AD is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Etropal AD dividend yield?

Etropal AD does not currently pay a dividend.

Does Etropal AD pay a dividend?

Etropal AD does not currently pay a dividend.

When does Etropal AD next pay dividends?

Etropal AD does not currently pay a dividend.

How do I buy Etropal AD shares?

To buy shares in Etropal AD you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Etropal AD?

Shares in Etropal AD are currently trading at BGN5.7, giving the company a market capitalisation of £12.6m.

Where are Etropal AD shares listed? Where are Etropal AD shares listed?

Here are the trading details for Etropal AD:

Country of listing: Bulgaria
Exchange: BLG
Ticker Symbol: ETR
What kind of share is Etropal AD?

Based on an overall assessment of its quality, value and momentum, Etropal AD is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Etropal AD share price forecast 2021?

We were not able to load any forecast data for Etropal AD.

How can I tell whether the Etropal AD share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Etropal AD. Over the past six months, the relative strength of its shares against the market has been -12.14%. At the current price of BGN5.7, shares in Etropal AD are trading at 2.39% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Etropal AD PE Ratio?

The Etropal AD PE ratio based on its reported earnings over the past 12 months is 1.01k. The shares are currently trading at BGN5.7.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Etropal AD?

Etropal AD's management team is headed by:

Nikolay Penchev - IND
Plamen Patev - CEO
Rositsa Pencheva - CAO
Maya Ivanova - DIR
Ivaylo Stoyanov - CHM
Who are the major shareholders of Etropal AD?

Here are the top five shareholders of Etropal AD based on the size of their shareholding:

Sintetika AD Corporation
Percentage owned: 51.01% (2.55m shares)
Similar to ETR
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.